Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers found that lasofoxifene outperformed fulvestrant in reducing primary tumor growth and preventing metastasis in the lung, liver, bone, and brain. Additionally, lasofoxifene prevents unwanted side effects, including menopausal-like symptoms.
Researchers find a way to target both pancreatic cancer cells and the scar tissue surrounding them, reducing tumor growth and spreading. A new clinical trial aims to test this approach with an existing anti-arthritis drug, potentially improving treatment response and patient survival.
A new four-drug combination treatment has shown promise in preventing cancer metastasis without triggering drug resistance. The treatment targets multiple pathways to suppress cancer cell spread and may help identify patients who would benefit from such therapy.
A phase II study by Penn Medicine shows rucaparib helped control cancer growth in patients with BRCA or PALB2 genetic mutations. The results support the use of rucaparib as a maintenance therapy for pancreatic cancer patients, offering a safe and effective alternative to chemotherapy.
A new study suggests that CDK4 and CDK6 inhibitors can improve immune-cell therapies for treating recurrent ER-positive metastatic breast cancer. The study found that these inhibitors cause breast tumors to secrete chemokines that attract T cells, improving patients' response to cancer immunotherapies.
A UMass Amherst research team has engineered a nanoparticle that can deliver cancer-fighting drugs to specific cells, reducing side effects. The innovation combines biologics and antibody-drug conjugates, enabling safer treatments for various genetic diseases.
A patient support program for people with autoimmune diseases and complex medication regimens can help them avoid using opioids or reduce their use. The study found that patients in the program were 13% less likely to start taking opioid pain medications and 26% less likely to fill two or more opioid prescriptions.
Researchers found that tumors can take up significant amounts of nanoparticle albumin-bound paclitaxel and that manipulating signaling pathways involved in nutrient uptake can enhance its consumption, boosting treatment efficacy
A team of researchers led by Lehigh University's Damien Thévenin is studying the connections between a protein called PTPRJ and human health. They aim to develop therapies that could overcome resistance to current treatments and provide new hope for cancer patients.
A Yale-led study found that new medicines and vaccines approved for use in the US are often not accessible in countries where they were developed, highlighting gaps in access to new medications. The study suggests that governments of host countries should require pharmaceutical companies to commit to submitting marketing approval appli...
A recent study analyzing 156,570 hospitalized patients found that anti-infective agents, cancer medications, and nonsteroidal anti-inflammatory drugs were the most toxic to the liver. Voriconazole, an antifungal medication, was associated with the highest incidence of drug-induced liver injury.
Researchers at Federal University of Rio de Janeiro discover a crucial link between phase transition and cancer pathology. Mutant p53 aggregates are formed through liquid-to-liquid phase separation, progressing to a gel-like or solid-like state that plays a key role in cancer development.
A new study by UCLA researchers identified a novel combination therapy using immune checkpoint inhibitors with ATRA to potentially overcome resistance to immunotherapy in LKB1-deficient lung cancer. The therapy led to eradication of over 70% of tumors and generated durable tumor-specific immunity.
A new study published in Blood Advances has identified a gene variant, mesothelin (MSLN), that is abnormally expressed in more than one-third of childhood and young adult AML cases. This discovery could lead to the development of precision medicine treatments for children with AML.
A UCLA team discovered a molecule that allows cancer stem cells to bypass the immune system, leading to increased growth and spread of head and neck squamous cell cancers. Inhibiting this molecule has been shown to disrupt cancer progression and eliminate these stem cells.
Researchers are testing cognitive behavioral therapy called Memory and Attention Adaptation Training (MAAT) to improve memory problems and emotional resilience among breast cancer survivors. The study aims to evaluate the effects of MAAT and supportive therapy on cognitive dysfunction after chemotherapy.
Researchers discovered that deleting the aryl hydrocarbon receptor from oral cancer cells results in a robust tumor-specific immune response, allowing mice to reject the cancer. This finding provides a new target for cancer immunotherapy treatment, potentially leading to more effective treatments.
A computational method using machine learning and feature sets derived from molecular simulation can predict the functional consequences of genetic variation in cancer drugs. This technology has the potential to accurately diagnose cancer variants and improve treatment outcomes by tailoring therapy to individual genetic profiles.
University of East Anglia researchers develop a new method for 3D printing medicine in highly porous structures, allowing for tailored drug release rates and improved patient outcomes. The technology has the potential to produce customized pills with accurate doses and reduced side effects.
A study published in Nature Communications found that rucaparib is effective in treating ovarian cancers with inherited or somatic mutations in DNA repair genes. The drug targets the Achilles heel of cancers with defects in DNA repair, outperforming chemotherapy in early treatment stages.
Merck Animal Health donates $100,000 to Morris Animal Foundation for animal cancer studies, doubling impact through the Stop Cancer Furever campaign. The funding supports groundbreaking research aimed at treating and preventing cancers in companion animals.
New research reveals patients with multiple comorbidities are more likely to be screened for colorectal cancer than those without any health conditions. Regular screenings significantly reduce cancer mortality.
Researchers have discovered that nanoparticles containing chemotherapy drug Capecitabine can attach to diseased cells, bypassing healthy ones and reducing toxic side effects. This targeted delivery system has shown promising results in animal experiments, improving cancer treatment outcomes.
The Digital Display Precision Predictor (DDPP) is a global biomarker model that predicts the duration of progression-free survival for cancer patients undergoing targeted therapy. It provides insight into the status of activation of almost all drug targets in tumor progression, enabling optimal treatment selection.
Researchers developed a topical cream using BRAF inhibitor LUT014 to reduce skin rash caused by EGFR inhibitors in colorectal cancer patients. The study showed that the treatment improved skin condition and reduced severity of the rash in 6 out of 10 patients.
Researchers discovered that targeting androgen receptors can destroy bladder cancer cells. The study found a common protein variant in malignant bladder tumor cells, which could lead to new therapeutic strategies.
A new study from the University of Missouri School of Medicine found that people of color, those with a higher income, and younger individuals are more likely to participate in cancer clinical trials. The analysis of 20,053 respondents showed an average overall clinical trial participation rate of 6.51%, with significant differences in...
A combination of inexpensive oral medications may treat fatigue-inducing anemias, a new discovery suggests. The therapy targets the root cause of anemia: disrupted cellular organelles, specifically the Golgi apparatus.
Researchers identified DUSP16 as a protein that promotes chemotherapy resistance in four types of cancer. Elevated DUSP16 levels can lead to reduced treatment effectiveness, highlighting its potential use as a biomarker for sensitivity to chemotherapy.
Scientists have developed a new class of cancer drug targeting enzymes that play a key role in translating DNA into proteins. This approach shows promising results in treating acute myeloid leukaemia, with the drug significantly reducing cancer cell growth and proliferation.
Recent studies at VCU Massey Cancer Center discovered a link between prolactin and breast cancer development. The hormone was found to act as a major contributor to breast cancer growth and could inform the creation of targeted drugs to treat multiple forms of the disease.
A new study published in Diagnostics demonstrates that artesunate, a drug synthesized from Artemisia annua, kills ovarian cancer cells. The researchers found anticancer activity at achievable concentrations, supporting the clinical development of this strategy.
Researchers at Ohio State University Comprehensive Cancer Center identified distinct mutational and molecular changes in four SCLC subtypes, providing new insights into treatment resistance. The findings suggest that subtyping patients before systemic therapy could play a role in drug development and therapy selection.
Dr. David Lyden, a Weill Cornell Medicine physician-scientist, has been inducted into the Association of American Physicians for his pioneering work on cancer metastasis and spread. His research reveals that tumors produce factors that prime distant organs to become hospitable sites for cancer growth.
A new analysis published in Psycho-Oncology found that fear of cancer recurrence leads to increased use of healthcare resources by cancer survivors. Implementing existing effective interventions for fear of cancer recurrence may improve both mental health and reduce unnecessary healthcare usage.
The COVID-19 pandemic had a significant impact on prescription drug spending in the US, with increased utilization and uptake of biosimilars driving growth. Specialty medications are also expected to play a major role in shaping future drug expenditures.
A new study from Ohio State University reveals that women with high-risk profiles struggle to access genetic counseling and testing due to financial constraints. The research emphasizes the need for greater transparency in healthcare pricing and policies to eliminate barriers to early cancer detection.
A global phase 3 clinical study confirms the effectiveness of targeted antibody drug conjugates against refractory metastatic triple-negative breast cancer. The ADC drug sacituzumab govitecan delivered a high dose of a cancer-killing drug to tumor cells, improving progression-free and overall survival.
A chemist at Purdue University has found a way to synthesize a compound that can fight a previously 'undruggable' cancer protein with benefits across various cancer types. The compound, curcusone D, was discovered in a shrub native to North America and has shown potent anti-cancer activity against breast cancer cells.
Researchers at VCU Massey Cancer Center have identified a protein called PLK3 that operates with mutated p53 genes to spur lung cancer growth. Inhibiting PLK3 has been shown to reduce tumor cell formation and proliferation in preclinical models of lung cancer.
The company's Abiprot technology identifies antibody binding sites on native-state, disease-relevant proteins at high resolution. The platform has the potential to bring game-changing benefits to large populations of patients suffering from uncurable diseases.
Australian researchers have discovered a new therapeutic approach for treating Diffuse Intrinsic Pontine Glioma (DIPG), a currently incurable brain cancer in children. Using the anti-cancer compound CBL0137, which targets the key genetic driver of DIPG, has shown promising results in both laboratory tests and animal models.
A new study reveals a long-sought enzyme, AMBRA1, that prevents cancer by controlling proteins driving cell growth. The findings also suggest that an existing drug class may be able to reverse such defects in the future.
Researchers at University Health Network found that combining immune-boosting drugs with radiation and surgery increased survival and anticancer immune response in mouse models of mesothelioma. The treatment extended survival and provided a durable immune response, even after re-injection of tumour cells up to 12 weeks later.
A new study suggests that immunotherapies combined with phenformin may be an effective way to fight cancer. Researchers found that phenformin has structural and therapeutic advantages over its sister compound metformin, which was previously used as an anti-diabetic agent.
Researchers at Ohio State University suggest that an oral drug currently used to treat neuromuscular diseases could help prevent a common form of skin cancer caused by UVB radiation. The study found that the neurotransmitter dopamine can stop the development and progression of certain UVB-induced precancerous squamous skin cancers.
Researchers propose a novel therapeutic strategy combining temozolomide with dianhydrogalactitol to overcome resistance mechanisms in glioblastoma. The combination shows synergistic effects in slowing tumour growth, suggesting a promising new approach for treating aggressive brain tumors.
A new algorithm can predict which genes cause cancer without DNA sequence changes. Researchers have identified 165 previously unknown cancer genes using machine learning technology, interacting closely with well-known cancer genes.
A large-scale study found that 25.1% of patients on immune checkpoint inhibitors developed skin-related side effects, including itching, inflammation, and rash. The study identified 10 specific conditions at higher risk among melanoma or kidney cancer patients.
Researchers at Dana-Farber Cancer Institute found that patients with non-small cell lung cancer and low aneuploidy levels tend to have better outcomes following treatment with immune checkpoint inhibitors. These findings suggest that aneuploidy testing can help determine which treatment is most likely to benefit patients.
A new combination drug therapy using a live common cold virus has demonstrated safety and efficacy against advanced skin cancer. The treatment shrunk melanoma tumors in nearly half of patients, with some experiencing complete remission.
Researchers at the Francis Crick Institute found that blocking a specific protein, DNPH1, sensitised BRCA-defective cancer cells to treatment with PARP inhibitors. The discovery suggests a promising potential treatment combination that could lead to improved therapy for patients with inheritable breast cancers.
Researchers have found a way to make cell cultures respond more closely to normal cells, allowing drugs to be screened for toxicity earlier in the research timeline. By changing two components of the media used to culture the cells, they can make liver cancer cells behave more like normal liver cells.
Researchers discovered a direct link between Parkin and the activation of mitophagy in Parkinson's, as well as its role in type 2 diabetes and cancer. The study found that AMPK, ULK1, and Parkin form a crucial pathway in cellular stress response.
Scientists have developed novel multi-stimuli-responsive drug delivery systems using hydrogels that can release drugs in response to temperature, pH, and reducing conditions. The hydrogels can control the amount of drug loaded onto them, ensuring effective delivery to target tumor sites.
Researchers at IRB Barcelona have discovered the HMCES enzyme to be a Achilles heel of some lung tumours with high mutations caused by the APOBEC system. Blocking HMCES is damaging to cancer cells but less so for healthy cells, making it a promising target for future treatments.
The Bertarelli Rare Cancers Fund has awarded over $9 million in grants to nine teams representing 19 lead investigators, advancing research into rare cancers that affect tens of thousands of patients annually. The fund aims to improve detection, diagnosis, treatment, and prevention of rare cancers through multidisciplinary collaborations.
Researchers have identified key mechanisms that enable cancer cells to resist therapies targeting mutated KRAS protein. The findings suggest a potential role for rational drug design and combination therapy in overcoming resistance.
Researchers at Niigata University have identified a protein biomarker, APM2, that can indicate the permissible level of the chemotherapeutic drug cisplatin. The study found a significant relationship between high APM2 expression and cisplatin resistance in liver and gastric cancer cells.
A study found that human tumor cells in patient-derived xenografts (PDX) are often compromised by mouse viruses, leading to false-positive results for cancer drug efficacy. The researchers analyzed 184 data sets and found that 170 samples showed the presence of mouse viruses.